Patients with recurrent Recurrent Glioblastoma Multiforme are increasingly being treated with reirradiation. Reirradiation is a viable Recurrent Glioblastoma Multiforme Treatment option despite the harm to normal brain tissue caused by high dose RT, thanks to technological advancements in radiation procedures, particularly breakthroughs in dose administration and treatment planning systems, which have increased the therapeutic ratio. Using either hypofractionated or conventionally fractionated radiation regimens, stereotactic radiosurgery (SRS) and stereotactic radiotherapy (SRT) have been associated with variable median survival periods of 6 to 12 months and neurological toxicity rates of 5% to 20%.
Moreover, reirradiation combined with temozolomide or bevacizumab has been shown to improve survival compared to reirradiation alone. With special attention to target volume delineation and the effects of radiation techniques on survival and the risk of radiation-induced brain necrosis, we present a clinical overview on the current status and advancements of reirradiation in the setting of recurrent or progressive GBM after standard treatment.
Antiangiogenic drugs like bevacizumab and alkylating drugs like temozolomide or lomustine are typical salvage therapy options for patients who get systemic Recurrent Glioblastoma Multiforme Treatment upon recurrence, leading to median survival durations of 6 to 12 months. Lomustine is the suggested second-line chemotherapy in the European Union based on a large randomised trial of 437 patients with progressive GBM that showed a similar median survival time of around 9 months for those receiving lomustine plus bevacizumab versus lomustine alone. Bevacizumab has been the standard salvage therapeutic option for patients with recurrent GBM since it was approved by the Food and Drug Administration in 2009.
Read More- https://coherentmarketinsightsus.blogspot.com/2023/02/other-malignancies-and-recurrent.html
ASCO: axi-cel in ZUMA-1Abstract No : 8012Abstract Type : Oral Abstract SessionIndication : Diffused Large B-Cell Lymphoma (DLBCL)Intervention : YescartaCompany : Kite, a Gilead CompanyTechnology : CAR T Cell TherapyBased on this limited sample size, reTx with axi-cel may have clinical efficacy, although transient, in some pts, especially those who achieve CR with 1st Tx.
CAR T cell expansion and severe CRS and NEs may be attenuated at reTx.
Further studies with additional pts are needed to confirm these results.View More: https://www.delveinsight.com/asco-conference/article/zuma-1 GSK: Cell Therapy and Next-generation Immuno-oncologyAt this year’s ASCO meeting, they will showcase presentations on investigational therapies, including belantamab mafodotin, an antibody-drug conjugate for multiple myeloma, and GSK3359609, an inducible T-cell co-stimulator (ICOS) agonist for patients with head and neck cancer.View More: https://www.delveinsight.com/asco-conference/article/gsk-cell-therapy-next-generation-immuno-oncology IMbrave150 TRIAL of AtezolizumabAtezo + Bev HCCIMbrave150 demonstrated statistically significant and clinically meaningful improvement in both OS and PFS with atezo + bev vs sor in pts with unresectable HCC who have not received prior systemic therapy.
Pts achieved CRs regardless of poor prognostic factors or etiology.
Atezo + bev may be a practice-changing treatment for pts with unresectable HCC.View More: https://www.delveinsight.com/asco-conference/article/imbrave150 ASCO: KEYNOTE-204Abstract No : 8005Abstract Type : Oral Abstract SessionIndication : Hodgkin’s Lymphoma (HL)Intervention : PembrolizumabCompany : Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.Technology : ImmunocheckpointIn pts with R/R cHL, pembro was superior to BV and demonstrated statistically significant and clinically meaningful improvement in PFS across all subgroups, with safety consistent with previous reports.
Pembro monotherapy should be standard of care for this pt population with R/R/cHL.View More: https://www.delveinsight.com/asco-conference/article/NCT02684292 ASCO: INO-5401 + INO-9012 with CemiplimabAbstract No : 2514Abstract Type : Oral Abstract SessionIndication : Glioblastoma MultiformeIntervention : INO-5401 and INO-9012 + CemiplimabCompany : Inovio PharmaTechnology : T cell therapy/Monoclonal AntibodyINO-5401 + INO-9012 in combination with cemiplimab and RT/TMZ has an acceptable safety profile, is immunogenic and may show a survival advantage in patients with newly-diagnosed GBM.View Report: https://www.delveinsight.com/asco-conference/article/NCT03491683
